Today's Rundown Vertex plunks down $950M for stem cell player Semma Therapeutics Clean safety and efficacy data tee Medicines Company up for PCSK9 scrap As Genfit hopes to get its liver drug on the market, founding CEO makes way for new blood Bayer nabs new dealmaker - but after Monsanto, is there enough cash? Achilles raises £100M for personalized T cell solid tumor trials Concert's alopecia drug sails through phase 2; phase 3 on deck for 2020 Another deadline, another delay for Roche’s Spark buy—and antitrust review's still to blame Featured Story | | | Tuesday, September 3, 2019 Vertex Pharmaceuticals is jumping into diabetes. The cystic fibrosis specialist is snapping up Semma Therapeutics and its stem cell-based diabetes treatments for $950 million in an all-cash deal slated to close in the fourth quarter. |
|
|---|
|
Top Stories Tuesday, September 3, 2019 In a close look at the top-line readout shared last week, The Medicines Company showed its siRNA inclisiran has a clean safety profile and is as effective as incumbent PCSK9 drugs sold by Amgen, Regeneron and Sanofi. Tuesday, September 3, 2019 As Genfit hopes for phase 3 successes and filings for its liver disease drug, its long-term CEO and co-founder Jean-François Mouney is stepping aside and promoting his executive vice president of marketing and commercial development to the top job. Tuesday, September 3, 2019 Bayer has hired Johnson & Johnson’s former business development chief Marianne De Backer PhD as its new head of business development and licensing of its pharma division. Tuesday, September 3, 2019 Achilles Therapeutics has raised a £100 million ($120 million) series B round. The financing sets Achilles up to run human proof-of-concept studies of its personalized T-cell therapies in two types of solid tumors. Tuesday, September 3, 2019 Two dose levels of Concert's alopecia drug beat placebo in phase 2, teeing it up to enter phase 3 in 2020. The drug is a deuterated version of ruxolitinib, a JAK inhibitor marketed by Incyte in the U.S. as Jakafi. Tuesday, September 3, 2019 September 3 has arrived, and Roche still can't move forward on its $4.8 billion Spark Therapeutics buyout. And once again, U.S. and U.K. anti-competition delays are the problem. Now, with less than a quarter of Spark shares tendered, the Swiss drugmaker is counting on an Oct. 1 deadline. | This week's sponsor is ExL Events. | | | |
Enrollment Showcase | | | October 23-25, 2019 | Chicago, IL | Presented by Biotech Primer BioImmersion: Biotech for the Non-Scientist is a three-day, in-depth course that delves into the scientific details on a broad number of biotechnology topics. Register today! |
|
|---|
|
Resources Sponsored by: AlphaSense AI-powered research tools are making it easier to source confident healthcare market intelligence with accuracy and efficiency -- download now to learn more about improving your competitive research strategy. Sponsored by: Elemental Machines Your lab is talking to you, are you listening? Sponsored by: Frenova Want to be sure your renal research protocol design is fit for the real world? Sponsored by: Recro Gainesville Vetting CDMOs but unsure what to look for in prospective partners’ multiproduct facilities? Sponsored by: Accenture Clinical trials are one of the pharma industry’s most painful and costly processes. Read how technology could transform the trial process from nine years to a matter of hours. Sponsored by: Baxter BioPharma Solutions Check out Baxter BioPharma Solutions’ whitepaper to learn considerations and options for developing a product in a prefilled syringe. Sponsored by: Alexander Group From sales headcount and budgets to new product launches and saying “yes” to millennials, hear the top 7 topics that are trending in sales compensation. Sponsored by: Wesco Pharmaceutical Solutions and WBR Insights The regulations and managing processes for hazardous, controlled and rare chemicals and biologics necessary for drug discovery are a huge distraction for R&D labs. Learn from the perspectives of industry executives the pain points and improvements they want in their processes for chemicals and biologics in pharmaceuticals R&D. Sponsored by: Kinaxis Download this life sciences industry spotlight to discover how concurrent planning can help you overcome complex supply chain challenges to drive down costs and improve efficiency. Sponsored by: Patheon, by Thermo Fisher Scientific Patheon, part of Thermo Fisher Scientific, offers advanced API manufacturing technologies such as continuous processing and continuous analytics to deliver high-quality products with well-defined features to meet your timelines and volume requirements. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. BioBasics: Biotech For The Non-Scientist Oct 22-23, 2019 | San Diego, CA BioImmersion: Biotech for the Non-Scientist October 23-25, 2019 | Chicago, IL 4th FierceBiotech Drug Development Forum October 28-29, 2019 | Boston, MA Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register NOW and start Pre-Boot Camp Preparation! | 